[xoo_el_inline_form active="login"]
Armed-T Product Pipeline
Armed-T Platform could develop more than 50 types of therapies
Unlocking Limitless Potential with CytoArm’s Armed-T Platform
Our Armed-T pipeline features a range of therapies that are in various stages of development,
Reflecting our Armed-T Platform could develop limitless innovative treatments to patients in need.
◆ CTA-002: Metastatic Colorectal Cancer (Click to watch videos on YouTube)👈
Our flagship product, CTA-002, features EGFR Armed-T cells designed to treat metastatic colorectal cancer by targeting the EGFR receptor. This therapy is currently under IND application in both Singapore and the U.S. CTA-002 is poised to become a breakthrough treatment option for patients with EGFR-expressing solid tumors, with the potential to significantly improve survival rates and quality of life. Future expansions may include other EGFR-expressing cancers, inlcluding Triple negative breast cancer (TNBC, Click to watch videos on YouTube)👈.
◆ CTA-003: Prostate Adenocarcinoma
CTA-03 involves the development of PSMA Armed-T cells targeting prostate adenocarcinoma, one of the most prevalent cancers among men. Now in the discovery phase, our research is focused on optimizing this therapy’s design and evaluating its therapeutic potential to meet the critical needs in prostate cancer treatment.
◆ CTA-004: Metastatic Breast Carcinoma
CTA-04 leverages HER-2 Armed-T cells in the fight against metastatic breast carcinoma, an aggressive and challenging cancer type. Our ongoing research aims to create a treatment that not only manages but potentially reduces the spread of metastatic breast cancer, bringing renewed hope to patients with this condition.
Co-Developing Products Pipelines
English 
Chinese